Wednesday, June 27, 2012

Gilead seeks FDA approval of HIV-fighter elvitegravir


Foster City-based Gilead (NASDAQ: GILD) filed a new drug application Wednesday with the Food and Drug Administration to market elvitegravir to people with the AIDS virus who have used other treatments.
Elvitegravir is combined with emtricitabine and tenofovir -- two compounds that together form Gilead's Truvada -- and a new Gilead-developed booster, called cobicistat, to form the Quad pill.

1 comment: